Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Símbolo de cotizaciónGRAL
Nombre de la empresaGrail Inc
Fecha de salida a bolsaJun 12, 2024
Fundada en2020
Director ejecutivoMr. Robert (Bob) Ragusa
Número de empleados1000
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
Dirección1525 O'brien Drive
CiudadMENLO PARK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94025
Teléfono18336942553
Sitio Webhttps://grail.com/
Símbolo de cotizaciónGRAL
Fecha de salida a bolsaJun 12, 2024
Fundada en2020
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos